Shopping Cart 0
Cart Subtotal
USD 0

Dilafor AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Summary

Dilafor AB (Dilafor) is a drug development company that develops pharmaceutical products for obstetric indications. The company offers tafoxiparin, a proprietary heparan sulfate mimetic, which is used as an adjuvant therapy to promote cervical ripening and myometrial contractility. Its tafoxiparin helps to improve uterine contractions and promote cervical softening and potential to reduce the incidence of protracted labor and associated complications. Dilafor carries out clinical trials to evaluate the safety and pharmacokinetics of tafoxiparinfor and other various indications within the obstetric field in Sweden and Finland. The company works in partnership with other pharmaceutical companies. Dilafor is headquartered in Solna, Sweden.

Dilafor AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dilafor AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Dilafor AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Dilafor AB, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Dilafor Raises USD6 Million in Venture Financing 10

Licensing Agreements 11

Dilafor Enters Into Licensing Agreement With Lee's Pharma 11

Acquisition 12

BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For USD 34 Million 12

Dilafor AB-Key Competitors 15

Dilafor AB-Key Employees 16

Dilafor AB-Locations And Subsidiaries 17

Head Office 17

Appendix 18

Methodology 18

About GlobalData 18

Contact Us 18

Disclaimer 18


List Of Figure

List of Figures

Dilafor AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dilafor AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Dilafor AB, Pharmaceuticals & Healthcare, Key Facts 2

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dilafor AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Dilafor AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dilafor AB, Deals By Therapy Area, 2012 to YTD 2018 8

Dilafor AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Dilafor Raises USD6 Million in Venture Financing 10

Dilafor Enters Into Licensing Agreement With Lee's Pharma 11

BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For USD 34 Million 12

Dilafor AB, Key Competitors 15

Dilafor AB, Key Employees 16

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com